Gyre Therapeutics, Inc. GYRE Change In Fair Value Of Derivative Liabilities
Change In Fair Value Of Derivative Liabilities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:ChangeInFairValueOfDerivativeLiabilities.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s change in fair value of derivative liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s change in fair value of derivative liabilities?
- Gyre Therapeutics, Inc. (GYRE) reported change in fair value of derivative liabilities of $39K in Q1 2025.
- How has Gyre Therapeutics, Inc.'s change in fair value of derivative liabilities changed year-over-year?
- Gyre Therapeutics, Inc.'s change in fair value of derivative liabilities decreased by 32.8% year-over-year, from $58K to $39K.
- What does change in fair value of derivative liabilities mean?
- Captures the non-cash gain or loss resulting from the revaluation of derivative financial instruments at fair value. This metric highlights the impact of market fluctuations on the company's hedging activities or financial obligations. It is essential for evaluating the volatility introduced by financial derivatives.